Seeking Alpha

Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ...
AHA/ASA Journals

Pulsed Field Ablation Versus Sham to Treat Atrial Fibrillation: The PFA-SHAM Randomized Clinical Trial

BACKGROUND: Catheter ablation for atrial fibrillation (AF) is one of the most common cardiovascular procedures being performed worldwide. Despite the large body of evidence of its effectiveness, with ...
Healio

New pulsed field ablation catheter safe, effective for paroxysmal AF: First-in-human data

Please provide your email address to receive an email when new articles are posted on . AF ablation with a novel contact force-sensing pulsed field catheter was safe and acutely effective. Three-month ...
Healio

FDA approves next-gen pulsed field ablation catheter for paroxysmal atrial fibrillation

Please provide your email address to receive an email when new articles are posted on . The FDA approved a navigation-enabled ablation catheter for the treatment of ...
FierceBiotech

Boston Scientific’s navigation-equipped pulsed field ablation catheter passes FDA

Boston Scientific collected a set of FDA green lights for an update to its pulsed field ablation system for atrial fibrillation, allowing it to combine cardiac mapping sensors and therapy delivery in ...
MD&M East

Zapping Afib: How Pulsed Field Ablation is Electrifying a $10B Market

Boston Scientific leads the pulsed field ablation (PFA) technology market to treat atrial fibrillation (Afib). But it is by no means alone in its commitment to this relatively new way to treat some ...
Business Wire

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the late-breaking ...
Business Wire

Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or ...
Hosted on MSN

Pulsed field ablation safety issues: Will newer devices clear the stumbling block?

In April, we reported on a study that raised alarms for safety issues with pulsed field ablation for atrial fibrillation. In this report, we follow up on subsequent developments for this technology.
FierceBiotech

Kardium grabs FDA approval for Globe pulsed field ablation catheter in afib

Kardium has collected an FDA approval for its pulsed field ablation approach to treating atrial fibrillation, giving it the go-ahead to compete in the emerging sector against heavyweights such as ...
MD&M East

Catheter Component Suppliers of Pulsed Field Ablation for Afib Encouraged by Growth

Medical device suppliers that produce parts and components for pulsed field ablation (PFA) catheters designed to treat atrial fibrillation (AFib) are optimistic about growth since Medtronic’s ...
Morningstar

Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking ...